SCHEMBL7354547

SCHEMBL7354547

Cc1cc(-c2nnc3c4ccccc4c(-c4ccccn4)nn23)no1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 9/20 0.64
GABRG2 P18507 9/20 0.64
GABRB3 P28472 9/20 0.64
GABRA5 P31644 9/20 0.64
GABRA3 P34903 9/20 0.64
GABRA2 P47869 9/20 0.64
GABRA4 P48169 1/20 0.64
GABRA6 Q16445 1/20 0.64
CACNA2D1 P54289 1/20 0.46
RXFP1 Q9HBX9 2/20 0.44
MAPT P10636 4/20 0.43
THRB P10828 1/20 0.43
HSD17B10 Q99714 2/20 0.40
TP53 P04637 2/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
POLB P06746 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7479045 0.83 GABRA1 (0.53) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL31058084 0.79 GABRA1 (0.58) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL7475422 0.79 GABRA1 (0.58) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL1258627 0.79 GABRA1 (0.58) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL2461190 0.78 GABRA1 (1.00) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL7208520 0.77 GABRA1 (0.56) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL6847244 0.77 GABRA1 (0.74) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL7960279 0.75 GABRA1 (0.47) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL7209133 0.74 GABRA1 (0.53) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL7479860 0.74 GABRA1 (0.83) GABRA1GABRG2GABRB3GABRA5GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455552-B1 ARECHOLINE AND 3-(5-METHYLISOXAZOL-3-YL)-6-(1-METHYL-1,2,3-TRIAZOL-4-YL)METHY LOXY-1,2,4-T RIAZOLO(3,4-A)PHTHALAZINE SUBTYPE FOR SEPARATE, SEQUENTIAL OR SIMULTANEOUS ADMINISTRATION. MERCK SHARP & DOHME LTD. 2002-09-24 US disclosed
US-6440967-B1 Combination of a GABAA alpha 5 inverse agonist and COX-2 inhibitor, NSAID, estrogen or vitamin E MERCK & CO., INC. 2002-08-27 US disclosed
EP-1131102-A2 COMBINATION OF A GABA-A ALPHA 5 INVERSE AGONIST AND COX-2 INHIBITOR, NSAID, ESTROGEN OR VITAMIN E Merck & Co., Inc. (US) 2001-09-12 EP disclosed
EP-1061925-A1 COMBINATION OF A GABA-A ALPHA 5 INVERSE AGONIST AND A NICOTINIC AGONIST MERCK SHARP & DOHME LTD. (GB) 2000-12-27 EP disclosed
WO-2000027382-A2 COMBINATION OF A GABA-A ALPHA 5 INVERSE AGONIST AND COX-2 INHIBITOR, NSAID, ESTROGEN OR VITAMIN E MERCK & CO., INC. (US) 2000-05-18 WO disclosed
WO-1999047171-A1 COMBINATION OF A GABA-A ALPHA 5 INVERSE AGONIST AND A MUSCARINIC AGONIST MERCK SHARP & DOHME LIMITED (GB) 1999-09-23 WO disclosed
WO-1999047142-A1 COMBINATION OF A GABA-A ALPHA 5 INVERSE AGONIST AND A NICOTINIC AGONIST MERCK SHARP & DOHME LIMITED (GB) 1999-09-23 WO disclosed